A month after a journalism investigation that led to resignations and turmoil at Memorial Sloan Kettering Cancer Center in New York, researchers including a Sloan Kettering scientist have quietly corrected at least two papers to add disclosures of financial conflicts of interest.
The two corrections, in Chemistry of Materials, are dated October 8, 2018 and read: Continue reading In wake of media scrutiny, Sloan Kettering author adds financial disclosures
A researcher at the University of Kentucky who studies the cancer risks of toxic chemicals has retracted three papers.
All of the retraction notices, which appear in the Journal of Biological Chemistry, refer to some kind of image duplication. The papers were originally published between 2014 and 2017, with the 2014 paper cited 39 times, according to Clarivate Analytics’ Web of Science.
The address was supposed to be a triumphant inaugural speech.
On Friday, Leonid Eidelman, the incoming president of the World Medical Association (WMA), made up of representatives from national medical associations, stood up in front of the group’s members in Reykjavik, Iceland, and told them it was a great honor to become their leader.
The trouble was, his speech had lifted passages from various sources — including remarks one of his predecessors had given in 2014. The following morning, members of the Canadian Medical Association (CMA) — including Chris Simpson, who had delivered the original 2014 speech — made a motion for Eidelman to resign. When that failed, the CMA said it was leaving the WMA.
CMA president Gigi Osler said in a statement: Continue reading Canadian Medical Association leaves international group after president plagiarizes past president’s speech
Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance.
The week at Retraction Watch featured questions about what should happen to a paper published by Theranos; a replication of a famous paper on treatment of writer’s block that led to — well, you’ll see; a researcher joining our leaderboard’s top 10; and a data faker who became chief scientific officer of a cannabis product company. Here’s what was happening elsewhere: Continue reading Weekend reads: Views on the “grievance studies” hoax; universities play “pass the harasser;” what next for NEJM?
The chief scientific officer of a cannabis product company whose stock price has been hotter than a flaming joint (sorry) was known more than 18 months ago to have committed research misconduct while at the U.S. National Institutes of Health — casting a cloud of suspicion over the firm’s operations.
Marketwatch reported yesterday that the company, India Globalization Capital, which trades on the New York Stock Exchange as IGC, has at least nine other “red flags” for investors, from questions about its ability to manufacture cannabinoids to a history of trouble with the U.S. Securities and Exchange Commission.
Until August, the company’s stock had been trading below 50 cents per share. It began a dramatic rise, eventually reaching $13 per share. MarketWatch notes:
A surgeon in Scotland who mistook a tear duct for a brain tumor, operated on the wrong disc in another patient and eventually gave up his right to practice medicine in the UK has corrected a 2008 paper.
The reason: More confusion, it seems. Muftah Salem Eljamel says he mistook an image in the article as being from his hospital when it belonged to another surgeon at a hospital in Cardiff, some 460 miles distant. And oh, the image wasn’t what he thought it was to begin with. The Courier reported on the correction.
According to the notice, in the Journal of Neurosurgery: Continue reading Dr. What? From the mixed-up files of Muftah Salem Eljamel
Welcome to the Top 10, Fazlul Sarkar.
Sarkar, the cancer researcher formerly of Wayne State University who once tried to sue critics on PubPeer, has had another seven papers retracted. That makes a total of 40, and places him in the Top 10 of our leaderboard of authors with the most retractions.
Three of the retractions appear in Molecular Cancer Therapeutics and four are from PLOS ONE. All involve falsification of data; one article had been corrected earlier, in 2014. Continue reading Cancer researcher who once tried to sue critics is up to 40 retracted papers
In 1974, Dennis Upper published a paper — well, to be precise, a blank page — entitled “THE UNSUCCESSFUL SELF-TREATMENT OF A CASE OF “WRITER’S BLOCK.” There have been several attempts to replicate the work, which has become a classic among a certain cohort of academics.
Until late last month, however, there was no multidisciplinary attempt to replicate the study. (As best we can tell, anyway. Who has time to do a proper literature review these days?) Now there is, along with an editor’s note that calls it “an exceptionally fine piece of scholarship.” We felt the best way to celebrate this auspicious occasion — coming about as far on the calendar from April 1 as one can — would be to interview the corresponding author of the new paper, Matt Brodhead, of Michigan State University. Lucky for us, he did not suffer from writer’s block, so he could respond to our questions by email.
Q: We can’t find the actual paper, even though the editor’s note refers to “the article below.” Did you bury your results in the supplemental information?
Continue reading Researchers replicated a classic paper on unsuccessful treatment of writer’s block. Then they tried to write it up.
Last December, a group of scientists at a biotech firm published a paper on a “miniaturized, robotic clinical laboratory.” The technique, according to the authors, “would benefit patients and physicians alike.”
Nothing terribly unusual there. But what was — and what caught the eye of a Retraction Watch reader — was the name of the last author: Elizabeth Holmes.
Continue reading What should happen to a paper published by Theranos?
Kathy Partin, who served as director of the U.S. Office of Research Integrity (ORI) for just under two years until being removed from the post late in 2017, has a new position at the U.S. National Institutes of Health (NIH), Retraction Watch has learned.
As of yesterday (Sept. 30), Partin is intramural research integrity officer at the NIH. She replaces Melissa Colbert, who will be retiring. Continue reading Former director of U.S. research watchdog agency moves to NIH